Tags

Type your tag names separated by a space and hit enter

Advances in the diagnosis and treatment of latent tuberculosis infection.
Curr Opin Infect Dis. 2020 04; 33(2):166-172.CO

Abstract

PURPOSE OF REVIEW

This review describes the major developments in the rationale for treating latent tuberculosis infection; new approaches to identifying persons with latent infection who are most likely to progress to active disease; and the development of novel short-course regimens for treatment of latent tuberculosis.

RECENT FINDINGS

As many as one-third of the world's population has latent infection with Mycobacterium tuberculosis. Models demonstrate that tuberculosis will not be eliminated without large-scale treatment of persons with latent TB. Current tools for identifying persons at risk for active tuberculosis disease include TST and IGRA, which have poor positive predictive values. Newer approaches using gene expression profiling show promise and are being studied in the ongoing trials. Development of short-course regimens are a major advance in treatment of latent TB. Three months of rifapentine with isoniazid, 4 months of rifampin, and 1 month of rifapentine with isoniazid have been found to be noninferior to the standard 9 months of isoniazid.

SUMMARY

Progress towards TB elimination can be accelerated by instituting public health measures that take into account new developments in identifying and treating persons with latent tuberculosis infection who are most likely to progress to active disease.

Authors+Show Affiliations

Medical School for International Health, Ben Gurion University, Beersheva, Israel.Vagelos College of Physicians and Surgeons and Columbia University Medical Center, New York, New York, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32022744

Citation

Jung, Ye Eun Grace, and Neil W. Schluger. "Advances in the Diagnosis and Treatment of Latent Tuberculosis Infection." Current Opinion in Infectious Diseases, vol. 33, no. 2, 2020, pp. 166-172.
Jung YEG, Schluger NW. Advances in the diagnosis and treatment of latent tuberculosis infection. Curr Opin Infect Dis. 2020;33(2):166-172.
Jung, Y. E. G., & Schluger, N. W. (2020). Advances in the diagnosis and treatment of latent tuberculosis infection. Current Opinion in Infectious Diseases, 33(2), 166-172. https://doi.org/10.1097/QCO.0000000000000629
Jung YEG, Schluger NW. Advances in the Diagnosis and Treatment of Latent Tuberculosis Infection. Curr Opin Infect Dis. 2020;33(2):166-172. PubMed PMID: 32022744.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Advances in the diagnosis and treatment of latent tuberculosis infection. AU - Jung,Ye Eun Grace, AU - Schluger,Neil W, PY - 2020/2/6/pubmed PY - 2021/5/1/medline PY - 2020/2/6/entrez SP - 166 EP - 172 JF - Current opinion in infectious diseases JO - Curr Opin Infect Dis VL - 33 IS - 2 N2 - PURPOSE OF REVIEW: This review describes the major developments in the rationale for treating latent tuberculosis infection; new approaches to identifying persons with latent infection who are most likely to progress to active disease; and the development of novel short-course regimens for treatment of latent tuberculosis. RECENT FINDINGS: As many as one-third of the world's population has latent infection with Mycobacterium tuberculosis. Models demonstrate that tuberculosis will not be eliminated without large-scale treatment of persons with latent TB. Current tools for identifying persons at risk for active tuberculosis disease include TST and IGRA, which have poor positive predictive values. Newer approaches using gene expression profiling show promise and are being studied in the ongoing trials. Development of short-course regimens are a major advance in treatment of latent TB. Three months of rifapentine with isoniazid, 4 months of rifampin, and 1 month of rifapentine with isoniazid have been found to be noninferior to the standard 9 months of isoniazid. SUMMARY: Progress towards TB elimination can be accelerated by instituting public health measures that take into account new developments in identifying and treating persons with latent tuberculosis infection who are most likely to progress to active disease. SN - 1473-6527 UR - https://www.unboundmedicine.com/medline/citation/32022744/Advances_in_the_diagnosis_and_treatment_of_latent_tuberculosis_infection_ L2 - https://doi.org/10.1097/QCO.0000000000000629 DB - PRIME DP - Unbound Medicine ER -